152 related articles for article (PubMed ID: 1422085)
1. Reversal of the malignant phenotype by an anti-ras ribozyme.
Kashani-Sabet M; Funato T; Tone T; Jiao L; Wang W; Yoshida E; Kashfinn BI; Shitara T; Wu AM; Moreno JG
Antisense Res Dev; 1992; 2(1):3-15. PubMed ID: 1422085
[TBL] [Abstract][Full Text] [Related]
2. Suppression of EJ cells tumorigenicity.
Tone T; Kashani-Sabet M; Funato T; Shitara T; Yoshida E; Kashfian BI; Horng M; Fodstadt O; Scanlon KJ
In Vivo; 1993; 7(6A):471-6. PubMed ID: 8193263
[TBL] [Abstract][Full Text] [Related]
3. Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line.
Eastham JA; Ahlering TE
J Urol; 1996 Sep; 156(3):1186-8. PubMed ID: 8709343
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer.
Irie A; Anderegg B; Kashani-Sabet M; Ohkawa T; Suzuki T; Halks-Miller M; Curiel DT; Scanlon KJ
Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):341-9. PubMed ID: 10463078
[TBL] [Abstract][Full Text] [Related]
5. Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene.
Koizumi M; Kamiya H; Ohtsuka E
Gene; 1992 Aug; 117(2):179-84. PubMed ID: 1639266
[TBL] [Abstract][Full Text] [Related]
6. Neoplastic progression by EJ/ras at different steps of transformation in vitro of human uroepithelial cells.
Pratt CI; Kao CH; Wu SQ; Gilchrist KW; Oyasu R; Reznikoff CA
Cancer Res; 1992 Feb; 52(3):688-95. PubMed ID: 1310069
[TBL] [Abstract][Full Text] [Related]
7. Ribozyme against mutant K-ras mRNA suppresses tumor growth of pancreatic cancer.
Kijima H; Yamazaki H; Nakamura M; Scanlon KJ; Osamura RY; Ueyama Y
Int J Oncol; 2004 Mar; 24(3):559-64. PubMed ID: 14767540
[TBL] [Abstract][Full Text] [Related]
8. Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme.
Funato T; Shitara T; Tone T; Jiao L; Kashani-Sabet M; Scanlon KJ
Biochem Pharmacol; 1994 Oct; 48(7):1471-5. PubMed ID: 7945447
[TBL] [Abstract][Full Text] [Related]
9. Chromosome losses in tumorigenic revertants of EJ/ras-expressing somatic cell hybrids.
Pratt CI; Wu SQ; Bhattacharya M; Kao C; Gilchrist KW; Reznikoff CA
Cancer Genet Cytogenet; 1992 Apr; 59(2):180-90. PubMed ID: 1316224
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme.
Kashani-Sabet M; Funato T; Florenes VA; Fodstad O; Scanlon KJ
Cancer Res; 1994 Feb; 54(4):900-2. PubMed ID: 8313379
[TBL] [Abstract][Full Text] [Related]
11. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme.
Feng M; Cabrera G; Deshane J; Scanlon KJ; Curiel DT
Cancer Res; 1995 May; 55(10):2024-8. PubMed ID: 7743496
[TBL] [Abstract][Full Text] [Related]
12. A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines.
Chang MY; Won SJ; Liu HS
J Cancer Res Clin Oncol; 1997; 123(2):91-9. PubMed ID: 9030247
[TBL] [Abstract][Full Text] [Related]
13. Antisense-fos RNA causes partial reversion of the transformed phenotypes induced by the c-Ha-ras oncogene.
Ledwith BJ; Manam S; Kraynak AR; Nichols WW; Bradley MO
Mol Cell Biol; 1990 Apr; 10(4):1545-55. PubMed ID: 1690847
[TBL] [Abstract][Full Text] [Related]
14. Ribozyme as an approach for growth suppression of human pancreatic cancer.
Kijima H; Scanlon KJ
Mol Biotechnol; 2000 Jan; 14(1):59-72. PubMed ID: 10911615
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of c-Ha-ras gene expression by hammerhead ribozymes containing a stable C(UUCG)G hairpin loop.
Koizumi M; Kamiya H; Ohtsuka E
Biol Pharm Bull; 1993 Sep; 16(9):879-83. PubMed ID: 8268855
[TBL] [Abstract][Full Text] [Related]
16. [Ribozyme targeted the point-mutation of activated oncogene inhibits its expression in vivo].
Liu G; Chen Y; Zhao X; Dong Y; Chen D
Yi Chuan Xue Bao; 1996; 23(6):477-85. PubMed ID: 9084224
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma.
Theodorescu D; Cornil I; Fernandez BJ; Kerbel RS
Proc Natl Acad Sci U S A; 1990 Nov; 87(22):9047-51. PubMed ID: 2247480
[TBL] [Abstract][Full Text] [Related]
18. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice.
Gray GD; Hernandez OM; Hebel D; Root M; Pow-Sang JM; Wickstrom E
Cancer Res; 1993 Feb; 53(3):577-80. PubMed ID: 8425190
[TBL] [Abstract][Full Text] [Related]
19. Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells.
Zhang YA; Nemunaitis J; Tong AW
Mol Biotechnol; 2000 May; 15(1):39-49. PubMed ID: 10911621
[TBL] [Abstract][Full Text] [Related]
20. Suppression of tumorigenicity with continued expression of the c-Ha-ras oncogene in EJ bladder carcinoma-human fibroblast hybrid cells.
Geiser AG; Der CJ; Marshall CJ; Stanbridge EJ
Proc Natl Acad Sci U S A; 1986 Jul; 83(14):5209-13. PubMed ID: 3523486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
